A Surprising Vaccine Rival May Upset the Dreams of Anyone Holding Moderna and Pfizer Stock

Jason Hawthorne, The Motley Fool
·5-min read
A Surprising Vaccine Rival May Upset the Dreams of Anyone Holding Moderna and Pfizer Stock

A small team of 10 researchers began designing vaccine candidates shortly after the genetic sequence of the SARS-CoV-2 virus was made public last January. For the past decade, the team had worked on vaccines for the Zika virus and Ebola, as well as another coronavirus, MERS. If it works, it could throw the sales estimates for Moderna (NASDAQ: MRNA), Pfizer (NYSE: PFE), and others up in the air.